<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03301805</url>
  </required_header>
  <id_info>
    <org_study_id>RGC-1502-01</org_study_id>
    <nct_id>NCT03301805</nct_id>
  </id_info>
  <brief_title>A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rgene Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and recommended dose level (RDL)
      of BLEX 404 Oral Liquid combined with Gemcitabine monotherapy in a 28-day schedule.The
      secondary purpose is to assess the efficacy and safety of BLEX 404 Oral Liquid combined with
      Gemcitabine monotherapy at the recommended dose.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Dose-limiting toxicity (DLT) observation</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
    <description>Presence or absence of dose-limiting toxicity (DLT) related to BLEX 404 Oral Liquid for each patient during first cycle of Gemcitabine monotherapy to determine the recommended dose level (RDL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (PR + CR)</measure>
    <time_frame>12 weeks (3 cycle)</time_frame>
    <description>Overall response rate (PR + CR) after 4 cycles of combination use in BLEX 404 + Gemcitabine monotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall benefit rate (CR + PR + SD)</measure>
    <time_frame>12 weeks (3 cycle)</time_frame>
    <description>1. Overall benefit rate (CR + PR + SD) after at least 3 cycles of combination use of BLEX 404 plus Gemcitabine monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3/4 hematological toxicity</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
    <description>Rate of grade 3/4 hematological toxicity of each cycle.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>BLEX 404 Oral Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During Phase I study (dose escalation), a standard 3+3 design will be followed, and the dose range is 3 to 10 mg/kg BID. The recommended dose level (RDL) for the Phase II study is defined as the dose level with 0 to 1 DLT observed during cycle I of Gemcitabine monotherapy among 6 patients in the Phase I study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLEX 404</intervention_name>
    <description>BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle
28 days a cycle.</description>
    <arm_group_label>BLEX 404 Oral Liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 20 - 80 years old at the time of signing the ICF.

          2. Patients with pathologically proved adenocarcinoma of pancreatic cancer and diagnosed
             with inoperable/metastatic disease (previous systemic chemotherapy, neoadjuvant or
             adjuvant gemcitabine are acceptable, unless exclusion criteria met).

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 1 to 2.

          4. Adequate hematologic function defined as: absolute neutrophil count (ANC) &gt;= 2,000/μL;
             platelets count &gt;= 100,000/μL; hemoglobin must be &gt;= 10 g/dL (can be corrected by
             growth factor or transfusion).

          5. Adequate hepatic function defined as: serum bilirubin =&lt; 1.5-fold upper limit of
             normal (ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), and
             alkaline phosphatase (ALP) =&lt; 3-fold ULN (5-fold ULN if liver metastasis is observed).

          6. Adequate renal function with: serum creatinine =&lt; 1.3 mg/dL or calculated creatinine
             clearance &gt;= 60 mL/minute according to the Cockcroft and Gault formula.

          7. At least one measurable disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST) version 1.1.

          8. Women must be either of non-child bearing potential, or women with child-bearing
             potential agree to use effective a highly contraceptive method or a contraceptive
             implant, exception of hormonal contraception (estrogen/progesterone), during treatment
             from time of Screening Visit and after cessation of therapy at least 3 months.

          9. Planning to receive Gemcitabine monotherapy.

         10. Willing and able to comply with all aspects of the treatment protocol.

         11. Provide written informed consent.

        Exclusion Criteria:

          1. Patients with following treatment prior to Gemcitabine monotherapy: chemotherapy,
             immunotherapy, or biologic systemic anticancer therapy within 28 days of study entry.

          2. Pancreatic patients with prior history of Gemcitabine chemotherapy.

          3. Women who are pregnant or breastfeeding.

          4. Patients with brain metastasis.

          5. Patients with bone metastasis alone.

          6. Patients with autoimmune disease that requires systemic steroids or immunosuppression
             agents.

          7. Current enrollment in another clinical study or used any investigational drug or
             device within the past 28 days preceding informed consent.

          8. Known history of human immunodeficiency virus (HIV) infection.

          9. Existing anticancer treatment-related toxicities of Grades &gt;= 2 (except for alopecia
             and neuropathy) according to Common Terminology Criteria for Adverse Events (CTCAE
             v4.03).

         10. Patients with an active infection requiring systemic therapy.

         11. Patients are hepatitis C virus (HCV) carrier, and/or with active viral disease which
             is defined as hepatitis B virus (HBV) carrier with HBV DNA &gt; 2,000 IU/ml plus AST and
             ALT &gt; 3-fold ULN.

         12. History of concomitant medical conditions or infectious diseases that, in the opinion
             of the investigator, would compromise the patient's ability to safely complete the
             study.

         13. Ascertained hypersensitivity to investigational product, Gemcitabine or any of the
             excipients used in the study.

         14. Uncontrolled nausea or vomiting or any symptom that would prevent the ability to
             comply with daily BLEX 404 Oral Liquid treatment.

         15. Judged to be not applicable to this study by investigator such as difficulty of
             follow-up observation, psychiatric disorder, with any other serious diseases/medical
             history.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frank L. Liu</last_name>
    <phone>+886-2-87518701</phone>
    <phone_ext>18</phone_ext>
    <email>liu3763@bioliteinc.com</email>
  </overall_contact>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

